Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
United States
Honor Health Research Institute, Scottsdale, Arizona University of Arizona, Tucson, Arizona Stanford Cancer Institute, Palo Alto, California UCLA Hematology/Oncology - Santa Monica, Santa Monica, California Christiana Care Health Services, Newark, Delaware Norton Cancer Institute, Louisville, Kentucky Ochsner Clinic Foundation, New Orleans, Louisiana Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland American Oncology Partners of Maryland, Bethesda, Maryland Ichan School of Medicine at Mount Sinai, New York, New York Carolina BioOncology Institute, Huntersville, North Carolina Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Tranquil Research, Webster, Texas NEXT Virigina, Fairfax, Virginia